Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1
Heather Friberga, Luis J. Martineza, Leyi Lina, Jason M Blaylocka, Rafael A. De La Barrerab, Alan L. Rothmanc, Joseph Robert Putnaka, Kenneth H. Eckelsb, Stephen James Thomasa, Richard G. Jarmana, Jeffrey R. Curriera
- aViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
- bPilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
- cInstitute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island, USA
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Dengue is a tropical disease transmitted by mosquitoes, and nearly half of the world's population lives in areas where individuals are at risk of infection. Several vaccines for dengue are in development, including one which was recently licensed in several countries, although its utility is limited to people who have already been infected with one of the four dengue viruses. One major hurdle to understanding whether a dengue vaccine will work for everyone-before exposure-is the necessity of knowing which marker can be measured in the blood to signal that the individual has protective immunity. This report describes an approach measuring multiple different parts of immunity in order to characterize which signals one candidate vaccine imparted to a small number of human volunteers. This approach was designed to be able to be applied to any dengue vaccine study so that the data can be compared and used to inform future vaccine design and/or optimization strategies.